IMMP Soars 1688% as EPS Revisions Ignite Biotech Rally; IOVA Jumps 37%
Immutep (IMMP) rocketed 1,688.5% to $4.65 after its next-year EPS growth estimate was revised to 25.5% on September 27, leading a broad biotech rally. Iovance Biotherapeutics (IOVA) surged 37.2% to $14.82 following a raised FY2026 revenue outlook, while Cardinal Infrastructure, LuxExperience, and Rezolute added 5-9% on estimate revisions.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| IMMP | Healthcare | 2026-09-27 | N/A | +1688.5% |
| IOVA | Healthcare | 2026-09-24 | N/A | +37.2% |
| CDNL | Industrials | 2026-09-25 | N/A | +9.2% |
| LUXE | Consumer Cyclical | 2026-09-24 | +162.6pp | +8.0% |
| RZLT | Healthcare | 2026-09-24 | N/A | +5.1% |
Why did IMMP stock jump in September 2026?
IMMP jumped 1,688.5% from $0.26 to $4.65 after its forward EPS growth estimate was revised upward to 25.5% on September 27.
The extreme percentage gain reflects a low-priced ADR and heightened sensitivity to earnings estimate changes; no specific earnings-related news was found, so the move likely stemmed from sector-wide biotech momentum or broader analyst recalibrations. The lack of company-specific catalysts suggests the revision was driven by updated industry models or peer data. This sharp rally highlights how small-cap healthcare names can react violently to estimate revisions.
IMMP EPS revision history → · Screener snapshot from 2026-09-27 →
FAQ: IMMP
Why did IMMP stock jump 1688%?
IMMP soared 1,688.5% from $0.26 to $4.65 after its next-year EPS growth estimate was revised to 25.5% on September 27, 2026. The low starting price amplified the percentage move.
Is IMMP a buy after the rally?
The 25.5% EPS growth estimate is positive, but the 1,688% surge without company-specific news suggests speculative momentum. Investors should await upcoming financial reports for fundamental confirmation.
What is IMMP's EPS growth estimate?
Immutep's next-year EPS growth estimate is 25.5% as of September 30, 2026, following an upward revision detected on September 27.
Why did IOVA stock jump in September 2026?
IOVA stock jumped 37.2% to $14.82 from $10.80 after analysts raised its forward EPS growth estimate to 52.0% on September 24, and the company boosted FY2026 revenue guidance to $410-$420 million on September 29.
The raised outlook, up from $350-$370 million, reflects record Q2 product revenue of $99.3 million and strong demand for Amtagvi and Proleukin. Management cited increasing patient demand and manufacturing visibility, with the authorized treatment center network approaching 100 locations. The stock hit over two-year highs as the revised midpoint cleared consensus estimates.
IOVA EPS revision history → · Screener snapshot from 2026-09-24 →
FAQ: IOVA
Why did IOVA stock jump on September 29, 2026?
IOVA jumped 37.2% to $14.82 after raising FY2026 revenue guidance to $410-$420 million, well above consensus, and following a prior EPS growth estimate hike to 52.0%.
Is IOVA a buy after the rally?
IOVA's raised guidance implies nearly 60% annual revenue growth, and its EPS growth estimate is 52.0%. However, the stock already surged to two-year highs, so valuation and execution risks remain.
What caused Iovance's surge?
Iovance surged after raising FY2026 revenue guidance to $410-$420 million on September 29, 2026, driven by record Q2 Amtagvi sales and an expanded treatment center network.
Why did CDNL stock jump in September 2026?
CDNL stock rose 9.2% to $30.60 from $28.02 after its next-year EPS growth estimate was revised upward to 29.6% on September 25.
No earnings-related news was found in the window, so the gain likely reflects sector strength in industrials or broader economic optimism. The revision, while modest, signaled improving analyst expectations for the infrastructure firm. This steady climb contrasts with the volatile biotech moves, highlighting a more measured response to estimate changes.
CDNL EPS revision history → · Screener snapshot from 2026-09-25 →
FAQ: CDNL
Why did CDNL stock gain 9.2%?
CDNL rose 9.2% to $30.60 after its next-year EPS growth estimate was revised to 29.6% on September 25, 2026. The move aligned with general industrials sector momentum.
Is CDNL a buy after the recent gain?
The 29.6% EPS growth estimate supports a positive outlook, but without specific news, the gain may be sector-driven. Investors should monitor upcoming earnings for confirmation.
What is CDNL's EPS growth estimate?
Cardinal Infrastructure Group's next-year EPS growth estimate is 29.6% as of September 30, 2026, following an upward revision detected on September 25.
Why did LUXE stock jump in September 2026?
LUXE stock climbed 8.0% to $9.91 from $9.18 after its next-year EPS growth estimate was revised from 2118.8% to 2281.3% on September 24.
This massive estimate, though off a low base, reflects expectations of explosive earnings growth for the consumer cyclical firm. No company-specific news was found, suggesting the move may be tied to broader discretionary spending trends or analyst reassessments. The revision underscores how rapidly estimates can change for companies transitioning to profitability.
LUXE EPS revision history → · Screener snapshot from 2026-09-24 →
FAQ: LUXE
Why did LUXE stock rise 8%?
LUXE gained 8.0% to $9.91 after its next-year EPS growth estimate was raised to 2281.3% on September 24, 2026. The revision was the primary catalyst.
Is LUXE a buy after the EPS revision?
The 2281.3% EPS growth estimate is extraordinary but likely unsustainable. Investors should assess the underlying business fundamentals before buying.
What is LUXE's EPS growth estimate?
LuxExperience's next-year EPS growth estimate is 2281.3% as of September 30, 2026, revised upward from 2118.8%.
Why did RZLT stock jump in September 2026?
RZLT stock gained 5.1% to $4.14 from $3.94 after its next-year EPS growth estimate was revised upward to 49.7% on September 24, coinciding with fiscal Q4 and full-year 2026 financial results.
The company reported a cash position of $107.8 million and reduced R&D expenses, signaling improved financial discipline. No additional earnings-related news followed, but the estimate revision and business update provided a modest boost. The gain reflects cautious optimism for the rare disease-focused biotech.
RZLT EPS revision history → · Screener snapshot from 2026-09-24 →
FAQ: RZLT
Why did RZLT stock rise 5.1%?
RZLT rose 5.1% to $4.14 after its next-year EPS growth estimate was revised to 49.7% on September 24, 2026, alongside its fiscal year-end financial report.
Is RZLT a buy after the recent gain?
The 49.7% EPS growth estimate and $107.8 million cash position are positives, but the stock remains speculative. Consider pipeline progress and cash burn.
What is RZLT's EPS growth estimate?
Rezolute's next-year EPS growth estimate is 49.7% as of September 30, 2026, following an upward revision detected on September 24.
Today's top performers highlight the outsize impact of EPS estimate revisions, especially in small-cap biotech where low prices and high sensitivity can lead to explosive gains. While Iovance's surge is backed by tangible guidance, others like IMMP show how speculative momentum can drive extreme moves.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →